Terms: = Prostate cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Prognosis
18 results:
1. Longitudinal monitoring of cell-free DNA methylation in alk-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract] [Full Text] [Related]
2. Activated alk Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine prostate cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract] [Full Text] [Related]
3. Neurexophilin and PC-esterase domain family member 4 (NXPE4) and prostate androgen-regulated mucin-like protein 1 (PARM1) as prognostic biomarkers for colorectal cancer.
Liu YR; Hu Y; Zeng Y; Li ZX; Zhang HB; Deng JL; Wang G
J Cell Biochem; 2019 Oct; 120(10):18041-18052. PubMed ID: 31297877
[TBL] [Abstract] [Full Text] [Related]
4. Active Surveillance for prostate cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract] [Full Text] [Related]
5. Expression of LMO2 in prostate Carcinoma and Adjacent Prostatic Parenchyma.
Krušlin B; Vučić M; Mašić S; Kruljac I; Lež C; Ružić B; Spajić B; Ulamec M
Acta Clin Croat; 2018 Oct; 57(Suppl 1):56-60. PubMed ID: 30457249
[TBL] [Abstract] [Full Text] [Related]
6. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
Shou J; Zhang Q; Wang S; Zhang D
Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
[TBL] [Abstract] [Full Text] [Related]
7. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
[TBL] [Abstract] [Full Text] [Related]
8. Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging.
Yoon MY; Park J; Cho JY; Jeong CW; Ku JH; Kim HH; Kwak C
Investig Clin Urol; 2017 Jan; 58(1):12-19. PubMed ID: 28097263
[TBL] [Abstract] [Full Text] [Related]
9. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing prognosis in a Metastatic Castration-Resistant prostate cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
10. Effects of oxygen on the antigenic landscape of prostate cancer cells.
Ma T; Schreiber CA; Knutson GJ; Khattouti AE; Sakiyama MJ; Hassan M; Charlesworth MC; Madden BJ; Zhou X; Vuk-Pavlović S; Gomez CR
BMC Res Notes; 2015 Nov; 8():687. PubMed ID: 26581192
[TBL] [Abstract] [Full Text] [Related]
11. Survival with Newly Diagnosed Metastatic prostate cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract] [Full Text] [Related]
12. Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.
Zhang XJ; Liu P; Zhu F
Genet Mol Res; 2014 Jan; 13(2):4419-24. PubMed ID: 24615090
[TBL] [Abstract] [Full Text] [Related]
13. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
Donohue JF; Bianco FJ; Kuroiwa K; Vickers AJ; Wheeler TM; Scardino PT; Reuter VA; Eastham JA
J Urol; 2006 Sep; 176(3):991-5. PubMed ID: 16890678
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).
Cho D; Di Blasio CJ; Rhee AC; Kattan MW
Urol Oncol; 2003; 21(4):282-91. PubMed ID: 12954499
[TBL] [Abstract] [Full Text] [Related]
15. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.
Smaletz O; Scher HI; Small EJ; Verbel DA; McMillan A; Regan K; Kelly WK; Kattan MW
J Clin Oncol; 2002 Oct; 20(19):3972-82. PubMed ID: 12351594
[TBL] [Abstract] [Full Text] [Related]
16. [Risk of suffering from a second primary neoplasm in patients with bladder tumor].
Osca García JM; Morera Martínez JF; Catalá Barceló T; Alfonso Gil R; Ruiz Cerdá JL; Martínez Jabaloyas JM; Jiménez Cruz JF
Actas Urol Esp; 1994 Jun; 18(6):646-50. PubMed ID: 7942215
[TBL] [Abstract] [Full Text] [Related]
17. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group.
Mulders PF; Dijkman GA; Fernandez del Moral P; Theeuwes AG; Debruyne FM
Cancer; 1990 Jun; 65(12):2758-61. PubMed ID: 2187588
[TBL] [Abstract] [Full Text] [Related]
